23:28 , Oct 3, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Influenza virus Mouse studies suggest a vaccine based on multiple conformations of an HA1 epitope could help prevent influenza A infection. Crystallographic analyses of HA1 from four strains of influenza A virus identified five...
19:30 , Sep 10, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Influenza virus Mouse, rabbit and ferret studies suggest vaccines based on modified HA mRNA could help prevent infection by multiple strains of influenza A virus. The two vaccines consist of mRNA encoding HA from...
17:56 , Aug 29, 2018 |  BC Innovations  |  Distillery Techniques

Drug platforms; imaging

TECHNOLOGY: Structural analyses; other An electron microscopy-based method for identifying epitopes that elicit potent neutralizing antibodies could be used to guide the development of vaccines for infectious diseases. The method involves six steps: digesting animal-...
16:10 , Aug 16, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Colorectal cancer; lung cancer Cell culture studies identified a triple KRAS/NRAS/HRAS inhibitor that could help treat KRAS-mutant colorectal cancer and NRAS-mutant non-small cell lung cancer (NSCLC). Screening of a small molecule library, structure-based optimization...
22:49 , Aug 10, 2018 |  BC Extra  |  Preclinical News

New approach could identify Ras-blocking small molecules

With an eye on historically undruggable cancer target Ras, a University of Oxford team and colleagues devised a way to find small molecules that have the same qualities as Ras inhibitors too large to access...
19:58 , Jul 13, 2018 |  BC Week In Review  |  Company News

Otsuka acquiring antibody play Visterra

Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) is acquiring antibody developer Visterra Inc. (Waltham, Mass.) for $430 million in cash, the companies said on July 11. The deal gives Otsuka a pipeline based on Visterra's Hierotope...
18:50 , Jul 11, 2018 |  BC Extra  |  Company News

Otsuka acquiring antibody play Visterra

Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) is acquiring antibody developer Visterra Inc. (Waltham, Mass.) for $430 million in cash, the companies said Wednesday. The deal gives Otsuka a pipeline based on Visterra's Hierotope platform, which...
18:33 , Jun 29, 2018 |  BC Week In Review  |  Financial News

Kura, Zafgen price follow-ons

Kura Oncology Inc. (NASDAQ:KURA) and Zafgen Inc. (NASDAQ:ZFGN) each priced follow-ons of at least $60 million on June 28. Kura raised $67 million through the sale of 4 million shares at $16.75 in an offering...
18:41 , Jun 28, 2018 |  BC Extra  |  Financial News

Kura, Zafgen price follow-ons

Kura Oncology Inc. (NASDAQ:KURA) and Zafgen Inc. (NASDAQ:ZFGN) each priced follow-ons of at least $60 million Thursday. Kura raised $67 million through the sale of 4 million shares at $16.75 in an offering underwritten by...
23:31 , May 1, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Influenza virus; viral infection Cell culture studies suggest two sialylated IGHA1 isotype mAbs targeting HA could help treat influenza and Newcastle disease. The IGHA1 isotype mAbs consist of the variable regions of two previously...